Download Medical Notes on Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review

Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review Medical Notes

About This Presentation

Description:The year 2019 was a good year for biopharma, fueled by strong fourth quarter markets and deal making. After difficult 2018, the biopharma industry recovered commendably to do good in the year 2019. A fourth-quarter surge on the stock markets meant that many biopharma companies concluded the year on a good note, as investors ran to drug developers of all sizes. As far as medtech is concerned, with rise in big- and mid-cap share prices outpaced many best companies in biopharma. However, fourth quarter was difficult for medtech with IPO numbers declining and fewer FDA approvals. This made it a mixed year for the medtech sector. Download and check this Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review to understand which areas are doing good and which are struggling, as well as what this means for biotech and medtech in 2020.

Tags:Pharma, Biotech, Medtech, pharmaceutical, biopharma

Published on: Jun 29, 2020 | Views : 1805 | Downloads : 1

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

Accountable Care Organizations and Patient-Centered Medical Homes

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

Accountable Care Organizations and Patient-Centered Medical Homes

Consumer-Directed Healthcare

The Pharmaceutical Industry in Europe – Facts and Figure

Specialty Pharmacy and Biosimilars

Covid-19 Outbreak & Business Continuity - 4 Practical Recommendations

The financialisation of Big Pharma

A Blueprint for Improving the Security of the USA Pharmaceutical Supply Chain

Electrolyte Disorders

2020 US and global life sciences outlook

Biopharma Companies Join Forces to Fight COVID-19

HEALTH A TO Z